

## ABSTRACT OF THE DISCLOSURE

Medicine, in particular medications for treating blood losses, hypoxic and ischemic states, for improving a blood oxygen supply and for preserving isolated perfused organs and tissues. The inventive medical emulsion of perfluororganic compounds includes rapidly excretable perfluororganic compounds such as perfluordecalin, perfluoractilbromide, a perfluororganic additive embodied in the form of a mixture of perfluorinated tertiary amines and phospholipids in the form of a water-salt dispersion. The perfluordecalin and perfluoractilbromide are contained in the composition of the rapidly excretable perfluororganic compounds at a ratio ranging from 10:1 to 1:10. The mixture of perfluorinated tertiary amines is embodied in the form of the mixture of perfluorotripropylamine and the co-products thereof: cis- and trans-isomers perfluor-1-propyl 3,4-dimethylpirrolidone and perfluor-1-propyl-4-methyldiisopropylamine. The inventive method for producing the emulsion includes producing the water-salt dispersion of phospholipids, in homogenizing the perfluororganic compounds therein at a high pressure and in sterilization of the final emulsion. The storage life of the inventive emulsion in the unfrozen state thereof at a temperature of +4 °C is equal to at least 6 months during which the biocompatibility of the emulsion with a biological medium (blood, plasma or serum) is preserved.